Navigation Links
ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
Date:10/22/2007

WASHINGTON, DC OCTOBER 22, 2007 Late-breaking results from the ENDEAVOR IV trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that the Endeavor zotarolimus-eluting stent met the trials primary endpoint, demonstrating a similar overall safety profile (equivalent rates of death, heart attack, and repeat procedures) to the Taxus paclitaxel-eluting stent at 1 year.

In addition, the Endeavor stent showed a lower rate of less-severe (non-Q-wave) heart attacks at 30 days, but a higher rate of angiographic late loss (artery re-narrowing) at eight months compared to the Taxus stent.

The primary endpoint of the trial, non-inferiority as measured by target vessel failure (TVF) between the two stents, was met, said Martin B. Leon, MD, Founder and Chairman Emeritus, CRF and Professor of Medicine at Columbia University Medical Center. TVF occurred in 6.6 percent of patients receiving the Endeavor stent and 7.2 percent of patients receiving the Taxus stent, a difference that was not statistically significant. The Endeavor stent also demonstrated equivalence to Taxus in several long term measures.

At 12 months, the difference between the rates of target lesion revascularization with the Endeavor (4.5 percent) and Taxus (3.2 percent) stents was not statistically significant. Likewise, target vessel revascularization rates at 12 months were also similar (6.3 percent with Endeavor vs. 6.7 percent with Taxus).

Interestingly, at 30 days, rates of less-severe heart attacks were 0.5 percent with Endeavor compared with 2.2 percent with Taxus, a statistically significant difference. Late loss at eight months, meanwhile, was significantly greater with Endeavor (0.67 mm) compared with Taxus (0.42 mm).

Importantly, in the diabetic subset of 477 patients, Endeavor had similar efficacy compared with Taxus including target lesion revascularization and in-segment restenosis.

The Endeavor IV trial included 1,548 patients at 80 locations and was randomized to treatment with either the Endeavor or Taxus stent.


'/>"/>

Contact: David Harrison
david@harrisoncommunications.net
410-804-1728
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. ENDEAVOR III Trial Reports Key Findings on New-generation Stent
2. Human Genome Project Achieves Technological Triumph
3. A Village in Madhya Pradesh Achieves Total Sanitation
4. PRIMARY PULMONARY HYPERTENSION GENE DISCOVERED
5. Is caries in primary and permanent tooth related?
6. Evidence against use of Beta blockers as first choice in the treatment of primary hypertension
7. Shortage Of Funds In Primary Care Trust In UK
8. What Will Primary Care Look Like In England by 2015?
9. Primary Health Care MoU Signed on the Sidelines of the PBD
10. Primary Care centers to provide out patient treatment
11. Early Detection Of Primary Liver Cancer Would Save Millions Of Lives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has published a ... an astounding statement when he says that the entire Bible was written for the ... times so plainly that anyone should be able to see the time period. He ...
(Date:2/24/2017)... Emeryville, CA (PRWEB) , ... February 24, 2017 ... ... Esparza for qualifying into the Senior International Elite division on February 12th. ... All Around divisions at the elite qualifier competition held in Las Vegas, Nevada. ...
(Date:2/23/2017)... ... 23, 2017 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Miami Beach to host its Swirl: Miami Wine Tasting Event on March 28, ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... uncertainty in clinical trials, today announced that Premier Research, a leading clinical development ... , Clinical trials are becoming increasingly complex, due in part to an array ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Südkorea, 23. Februar 2017 LG Innotek ... Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls ... Strahlung im Bereich zwischen 200 und 280 nm und eignet ... Bakterien, indem es ihre DNA zerstört. Das Produkt von ... ...
(Date:2/23/2017)... , Feb. 23, 2017 ITL Limited, ( ASX: ... excellent results for the half year ended 31 December 2016 compared ... Growth Update" presentation can be viewed here . ... (Dec 2015: $1.04m; up 104%) Earnings per share ... Revenue of $17.5m (Dec 2015: $15.7m; up 11%) ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of the ... their offering. ... research Menopause Drugs Price Analysis and Strategies - 2016, provides drug pricing ... the following questions: What are the key ... in the Global Menopause market? What are the unit ...
Breaking Medicine Technology: